Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Rheumatology and Therapy, May 2017

Filip Van den Bosch, Andrew J. K. Ostor, Siegfried Wassenberg, Naijun Chen, Chen Wang, Vishvas Garg, Jasmina Kalabic

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs40744-017-0065-3.pdf

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study Filip Van den Bosch . Andrew J. K. Ostor . Siegfried Wassenberg . 0 1 2 3 Naijun Chen . Chen Wang . Vishvas Garg . Jasmina Kalabic 0 1 2 3 A. J. K. Ostor Addenbrooke's Hospital 0 1 2 3 Cambridge 0 1 2 3 UK 0 1 2 3 0 N. Chen C. Wang V. Garg AbbVie Inc. , North Chicago, IL , USA 1 S. Wassenberg Rheumazentrum , Ratingen , Germany 2 F. Van den Bosch (&) Ghent University Hospital and VIB Center for Inflammation Research , Ghent , Belgium 3 J. Kalabic AbbVie Deutschland GmbH & Co. KG , Ludwigshafen , Germany Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. - In the original publication, ADA treatment values mentioned in the results section, under the heading ‘Study Outcomes’ were published incorrectly. The correct text should read ‘‘Additionally, compared to PSP users, PSP non-users had significantly lower percentage of patients that started at PAM-13 level 4 at baseline and remained at level 4 until week 78 of ADA treatment (52.4% vs 28.9%, p = 0.001)’’.


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs40744-017-0065-3.pdf

Filip Van den Bosch, Andrew J. K. Ostor, Siegfried Wassenberg, Naijun Chen, Chen Wang, Vishvas Garg, Jasmina Kalabic. Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study, Rheumatology and Therapy, 2017, 97, DOI: 10.1007/s40744-017-0065-3